Splenic marginal zone lymphoma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
! style="background: #4479BA; width: 600px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}} | ! style="background: #4479BA; width: 600px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}} | ||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Cytogenetics'''}} | ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Cytogenetics'''}} | ||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|''' | ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Morphological Features'''}} | ||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|'''Immunophenotype'''}} | ! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|'''Immunophenotype'''}} | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Splenic marginal zone lymphoma''' | '''Splenic marginal zone lymphoma''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* Deletion 7q, [[trisomy]] 3, [[trisomy]] 12, [[trisomy]] 18, | * Deletion 7q, [[trisomy]] 3, [[trisomy]] 12, [[trisomy]] 18, | ||
* Genes mutation [[NOTCH2]], NFkB pathway genes (BIRC3, [[TNFAIP3]], [[MAP3K14]], IKBKB, [[MYD88]] L265P) | * Genes mutation [[NOTCH2]], NFkB pathway genes (BIRC3, [[TNFAIP3]], [[MAP3K14]], IKBKB, [[MYD88]] L265P) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center | | | style="padding: 5px 5px; background: #F5F5F5;" align=center | | ||
'''Negative''' | '''Negative''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* [[CD20]]+, [[CD79a]]+[[IgM]]+ | * [[CD20]]+, [[CD79a]]+[[IgM]]+ | ||
* [[CD11c]]+, [[IgD]]+, DBA44+ in more than 50% of the cases | * [[CD11c]]+, [[IgD]]+, DBA44+ in more than 50% of the cases | ||
* [[CD5]]+, [[CD25]]+, [[CD103]]+, [[IgG]]+ in less than 50% of the cases | * [[CD5]]+, [[CD25]]+, [[CD103]]+, [[IgG]]+ in less than 50% of the cases | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Splenic diffuse red pulp lymphoma''' | '''Splenic diffuse red pulp lymphoma''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center| | | style="padding: 5px 5px; background: #F5F5F5;" align=center| | ||
* Uncommon: 7q deletion, [[trisomy]] 18, 17p deletion ( [[TP53]]) | * Uncommon: 7q deletion, [[trisomy]] 18, 17p deletion ( [[TP53]]) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* Spleen | |||
| style="padding: 5px 5px; background: #F5F5F5;" align= | ** Macroscopic | ||
**Uniformly reddish brown with no tumor nodules | |||
*Microscopic | |||
**Obliteration of splenic architecture by neoplastic cells | |||
**Red pulp involvement with infiltration of both cord and sinuses | |||
**Effacement of white pulp | |||
*Bone Marrow | |||
**Extensive intrasinusoidal involvement | |||
*Peripheral blood | |||
**Wbcs with villous cytology | |||
| style="padding: 5px 5px; background: #F5F5F5;" align=left| | |||
* [[CD11c]]+,[[CD20]]+, [[CD79a]]+ DBA44+ | * [[CD11c]]+,[[CD20]]+, [[CD79a]]+ DBA44+ | ||
* [[IgM]]+, [[IgD]]+, [[IgG]]+ in more than 50% of the cases | * [[IgM]]+, [[IgD]]+, [[IgG]]+ in more than 50% of the cases | ||
| Line 41: | Line 49: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Hairy cell leukemia variant''' | '''Hairy cell leukemia variant''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* Common: Deletion 17p ( [[TP53]]), | * Common: Deletion 17p ( [[TP53]]), | ||
* Uncommon: 5q gain, deletion 7q | * Uncommon: 5q gain, deletion 7q | ||
| Line 47: | Line 55: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center| | | style="padding: 5px 5px; background: #F5F5F5;" align=center| | ||
'''Positive''' | '''Positive''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* [[CD11c]]+, [[ CD20]]+, [[CD79a]]+, [[CD103]]+, DBA44+ | * [[CD11c]]+, [[ CD20]]+, [[CD79a]]+, [[CD103]]+, DBA44+ | ||
* [[IgG]]+ in more than 50% of the cases | * [[IgG]]+ in more than 50% of the cases | ||
| Line 54: | Line 62: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Hairy cell leukemia''' | '''Hairy cell leukemia''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* Uncommon: 5q gain, 7q deletion | * Uncommon: 5q gain, 7q deletion | ||
* gene mutation: [[BRAF V600E]] | * gene mutation: [[BRAF V600E]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center| | | style="padding: 5px 5px; background: #F5F5F5;" align=center| | ||
'''Negative''' | '''Negative''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* [[CD11c]]+, [[CD20]]+, [[CD79a]]+, [[CD25]]+, [[CD103]]+, [[CD123]]+, [[Annexin A1]]+, [[IgM]]+, [[IgD]]+, [[IgG]]+ | * [[CD11c]]+, [[CD20]]+, [[CD79a]]+, [[CD25]]+, [[CD103]]+, [[CD123]]+, [[Annexin A1]]+, [[IgM]]+, [[IgD]]+, [[IgG]]+ | ||
* [[CD10]]+ in less than 50% of the cases | * [[CD10]]+ in less than 50% of the cases | ||
| Line 65: | Line 73: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Lymphoplasmacytic lymphoma''' | '''Lymphoplasmacytic lymphoma''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* Common: 6q deletion, | * Common: 6q deletion, | ||
* Uncommon: 13q deletion, 7q deletion | * Uncommon: 13q deletion, 7q deletion | ||
| Line 71: | Line 79: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center| | | style="padding: 5px 5px; background: #F5F5F5;" align=center| | ||
'''Positive''' | '''Positive''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* [[CD11]]+,[[ CD20]]+, [[CD79a]]+ [[IgM]]+ | * [[CD11]]+,[[ CD20]]+, [[CD79a]]+ [[IgM]]+ | ||
* [[CD25]]+ in more than 50% of the cases | * [[CD25]]+ in more than 50% of the cases | ||
| Line 78: | Line 86: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Chronic lymphocytic leukemia''' | '''Chronic lymphocytic leukemia''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* Chromosomal deletion 6q, 7q, 13q, 17p | * Chromosomal deletion 6q, 7q, 13q, 17p | ||
* Trisomy 13 less frequently | * Trisomy 13 less frequently | ||
| Line 84: | Line 92: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center| | | style="padding: 5px 5px; background: #F5F5F5;" align=center| | ||
'''Negative''' | '''Negative''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* [[IgM]]+, [[IgD]]+, [[CD5]]+, [[CD23]]+, [[CD43]]+, [[CD79a]]+, [[LEF1]]+ | * [[IgM]]+, [[IgD]]+, [[CD5]]+, [[CD23]]+, [[CD43]]+, [[CD79a]]+, [[LEF1]]+ | ||
* [[CD20]]+, DBA44+ in less than 50% | * [[CD20]]+, DBA44+ in less than 50% | ||
| Line 90: | Line 98: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Follicular lymphoma''' | '''Follicular lymphoma''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* t(14;18) translocation | * t(14;18) translocation | ||
* gene mutation: BCL2 | * gene mutation: BCL2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center| | | style="padding: 5px 5px; background: #F5F5F5;" align=center| | ||
'''Positive''' | '''Positive''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* [[IgM]]+, [[IgD]]+, [[CD20]]+, [[CD79a]]+, [[BCL6]]+ | * [[IgM]]+, [[IgD]]+, [[CD20]]+, [[CD79a]]+, [[BCL6]]+ | ||
* [[CD10]]+ in more than 50% | * [[CD10]]+ in more than 50% | ||
| Line 102: | Line 110: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
'''Mantle cell lymphoma''' | '''Mantle cell lymphoma''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* t (11;14) translocation | * t (11;14) translocation | ||
* Gene mutation: CCND1 | * Gene mutation: CCND1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=center| | | style="padding: 5px 5px; background: #F5F5F5;" align=center| | ||
'''Negative''' | '''Negative''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align= | | style="padding: 5px 5px; background: #F5F5F5;" align=left| | ||
* [[IgM]]+, [[IgD]]+, [[CD5]]+, [[CD20]]+, [[CD43]]+, [[CD79a]]+, [[BCL1]]+, [[SOX11]]+ | * [[IgM]]+, [[IgD]]+, [[CD5]]+, [[CD20]]+, [[CD43]]+, [[CD79a]]+, [[BCL1]]+, [[SOX11]]+ | ||
* [[BCL6]]+ and LEF1+ in less than 50% for the cases | * [[BCL6]]+ and LEF1+ in less than 50% for the cases | ||
Revision as of 04:16, 3 January 2019
|
Splenic marginal zone lymphoma Microchapters |
|
Differentiating Splenic marginal zone lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Splenic marginal zone lymphoma differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Splenic marginal zone lymphoma differential diagnosis |
|
FDA on Splenic marginal zone lymphoma differential diagnosis |
|
CDC on Splenic marginal zone lymphoma differential diagnosis |
|
Splenic marginal zone lymphoma differential diagnosis in the news |
|
Blogs on Splenic marginal zone lymphoma differential diagnosis |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
|
Risk calculators and risk factors for Splenic marginal zone lymphoma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Splenic marginal zone lymphoma must be differentiated from other diseases such as chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma.[1]
Differential Diagnosis
Splenic marginal zone lymphoma(SMZL) must be differentiated from other splenic B-cell lymphomas with the help of clincal, morphological, immunophenotypic and genetic data as the treatment of all these conditions are different from each other.[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]
| Differential Diagnosis | Cytogenetics | Morphological Features | Immunophenotype |
|---|---|---|---|
|
Splenic marginal zone lymphoma |
Negative |
||
|
Splenic diffuse red pulp lymphoma |
|
||
|
Hairy cell leukemia variant |
Positive |
||
|
Hairy cell leukemia |
|
Negative |
|
|
Lymphoplasmacytic lymphoma |
|
Positive |
|
|
Chronic lymphocytic leukemia |
Negative |
||
|
Follicular lymphoma |
|
Positive |
|
|
Mantle cell lymphoma |
|
Negative |
References
- ↑ Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016
- ↑ Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (March 2008). "Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria". Leukemia. 22 (3): 487–95. doi:10.1038/sj.leu.2405068. PMID 18094718.
- ↑ Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F (September 2010). "Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group". Blood. 116 (9): 1479–88. doi:10.1182/blood-2010-02-267476. PMID 20479288.
- ↑ Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS (August 2012). "Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma". J. Exp. Med. 209 (9): 1553–65. doi:10.1084/jem.20120910. PMC 3428949. PMID 22891276.
- ↑ Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G (August 2012). "The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development". J. Exp. Med. 209 (9): 1537–51. doi:10.1084/jem.20120904. PMC 3428941. PMID 22891273.
- ↑ Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (June 2011). "BRAF mutations in hairy-cell leukemia". N. Engl. J. Med. 364 (24): 2305–15. doi:10.1056/NEJMoa1014209. PMID 21663470.
- ↑ Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS (January 2014). "High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias". Nat. Genet. 46 (1): 8–10. doi:10.1038/ng.2828. PMC 3905739. PMID 24241536.
- ↑ Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P (February 2008). "Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?". Blood. 111 (4): 2253–60. doi:10.1182/blood-2007-07-098848. PMID 18042795.
- ↑ Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R (May 2012). "Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities". Mod. Pathol. 25 (5): 651–60. doi:10.1038/modpathol.2011.213. PMC 3341516. PMID 22301699.
- ↑ Traverse-Glehen A, Bachy E, Baseggio L, Callet-Bauchu E, Gazzo S, Verney A, Hayette S, Jallades L, Ffrench M, Salles G, Coiffier B, Felman P, Berger F (May 2013). "Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases". Histopathology. 62 (6): 876–93. doi:10.1111/his.12092. PMID 23611359.
- ↑ Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ (April 2012). "Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation". Blood. 119 (14): 3330–2. doi:10.1182/blood-2011-09-379339. PMC 3321859. PMID 22210875.
- ↑ Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D (March 1994). "The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders". Blood. 83 (6): 1558–62. PMID 8123845.
- ↑ Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M (October 2011). "Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders". Am. J. Clin. Pathol. 136 (4): 625–30. doi:10.1309/AJCPKUM9J4IXCWEU. PMID 21917686.
- ↑ Ponzoni M, Kanellis G, Pouliou E, Baliakas P, Scarfò L, Ferreri AJ, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T (November 2012). "Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?". Am. J. Surg. Pathol. 36 (11): 1609–18. doi:10.1097/PAS.0b013e318271243d. PMID 23073320.
- ↑ Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, Foa R, Pulsoni A, Dalla Favera R, Pileri S (June 2004). "Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)". Lancet. 363 (9424): 1869–70. doi:10.1016/S0140-6736(04)16356-3. PMID 15183626.
- ↑ Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, Montalban C, Matutes E, Wotherspoon A, Piris MA (July 2010). "Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features". Haematologica. 95 (7): 1122–9. doi:10.3324/haematol.2009.013714. PMID 20220064.
- ↑ Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Manning RJ, Tripsas C, Patterson CJ, Sheehy P, Treon SP (March 2014). "The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis". Blood. 123 (11): 1637–46. doi:10.1182/blood-2013-09-525808. PMID 24366360.
- ↑ Went PT, Zimpfer A, Pehrs AC, Sabattini E, Pileri SA, Maurer R, Terracciano L, Tzankov A, Sauter G, Dirnhofer S (April 2005). "High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia". Am. J. Surg. Pathol. 29 (4): 474–8. PMID 15767800.
- ↑ Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED (June 2009). "Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia". Mod. Pathol. 22 (6): 807–16. doi:10.1038/modpathol.2009.34. PMID 19287458.